Figure 6
From: Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets
Biodistribution of 89 Zr-bevacizumab-IRDye800CW in tumor-bearing mice. Biodistribution of intravenously injected 89Zr-bevacizumab and 89Zr-bevacizumab-IRDye800CW (1 and 2 eq) in FaDu xenograft-bearing nude mice at 48 (A) and 72 (B) h after injection. Bars marked with an asterisk have an uptake that is significantly (P ≤ 0.05) different from the uptake of 89Zr-bevacizumab. Data are presented as %ID/g ± SD.